- PR Newswire•17 minutes agoAmgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
THOUSAND OAKS, Calif., Sept. 27, 2016 /PRNewswire/ -- Amgen (AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant. Overall, the adverse events in the KMP arm were consistent with the known safety profile of KYPROLIS. The incidence of Grade 3 or higher adverse events was 74.7 percent in the KMP arm and 76.2 percent in the VMP arm.
- PR Newswire•11 hours ago
CAMBRIDGE, Mass., Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities in Cambridge, Mass.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||172.00 x 400|
|Ask||178.98 x 100|
|Day's Range||172.83 - 174.42|
|52wk Range||131.43 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.76|
|Avg Vol (3m)||2,847,721|
|Dividend & Yield||4.00 (2.29%)|